A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 20, Issue 7, 2010, Pages 605-

  Brown, John V ^a   Micha, John P ^a   Rettenmaier, Mark A ^a   Abaid, Lisa N ^a   Lopez, Katrina L ^b   Goldstein, Bram H ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Women's Cancer Research Foundation   (United States)

Author keywords

Bevacizumab; Carboplatin; Gynecologic oncology; Ovarian cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; MONOCLONAL ANTIBODY; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER STAGING; CYSTADENOCARCINOMA; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; PAPILLARY CARCINOMA; PATHOLOGY; PERITONEUM TUMOR; PILOT STUDY; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE TUBE TUMOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PILOT PROJECTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79960679604     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181e94331     Document Type: Article

References (0)